Early detection of the PAX3‐FOXO1 fusion gene in circulating tumor‐derived DNA in a case of alveolar rhabdomyosarcoma. Issue 8 (10th February 2019)

• Record Type: Journal Article
• Authors: Eguchi‐Ishimae, Minenori; Tezuka, Mari; Kokeguchi, Tomoki; Nagai, Kozo; Moritani, Kyoko; Yonezawa, Sachiko; Tauchi, Hisamichi; Tokuda, Kiriko; Ishida, Yasushi; Ishii, Eiichi; Eguchi, Mariko
• Is Part Of: Genes, chromosomes & cancer. Volume 58:Issue 8(2019)
• Page Start: 521
• Page End: 529
• Publication Date: 2019-02-10
• Subjects: cell‐free DNA -- liquid biopsy -- PAX3‐FOXO1 -- rhabdomyosarcoma; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.22734
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Cell‐free DNA (cfDNA), which are small DNA fragments in blood derived from dead cells including tumor cells, could serve as useful biomarkers and provide valuable genetic information about the tumors. cfDNA is now used for the genetic analysis of several types of cancers, as a surrogate for tumor biopsy, designated as "liquid biopsy." Rhabdomyosarcoma (RMS), the most frequent soft tissue tumor in childhood, can arise in any part of the body, and radiological imaging is the only available method for estimating the tumor burden, because no useful specific biological markers are present in the blood. Because tumor volume is one of the determinants of treatment response and outcome, early detection at diagnosis as well as relapse is essential for improving the treatment outcome. A 15‐year‐old male patient was diagnosed with alveolar RMS of prostate origin with bone marrow invasion. The PAX3‐FOXO1 fusion was identified in the tumor cells in the bone marrow. After the diagnosis, cfDNA was serially collected to detect the PAX3‐FOXO1 fusion sequence as a tumor marker. cfDNA could be an appropriate source for detecting the fusion gene; assays using cfDNA have proved to be useful for the early detection of tumor progression/recurrence. Additionally, the fusion gene dosage estimated by quantitative polymerase chain reaction reflected the tumor volume during the course of the treatment. We suggest that for fusion gene‐positive RMSs, and other soft tissue tumors, the fusion sequence should be used for monitoring the tumor burden in the body to determine the diagnosis and treatment options for the patients.